Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-04-30

AUTHORS

S Maïga, P Gomez-Bougie, S Bonnaud, C Gratas, P Moreau, S Le Gouill, C Pellat-Deceunynck, M Amiot

ABSTRACT

Background:Lenalidomide is an active immunomodulatory and antiproliferative agent in multiple myeloma. However, the molecular mechanisms driving these activities are not yet fully elucidated. Therefore, we investigated the modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment.Methods:Lenalidomide effect on myeloma cell proliferation was investigated in a myeloma cell line collection (n=23) by 3H-thymidine incorporation. Modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment was analysed by real-time quantitative PCR.Results:Lenalidomide inhibits the proliferation of two-thirds of myeloma cell lines independently of their genetic background. We demonstrated that LEN increased TNF-α and IL-8 inflammatory cytokines and insulin-like growth factor-1 (IGF-1) growth factor in both sensitive and resistant myeloma cells to LEN.Conclusion:Lenalidomide favours a uniform TNF-α and IL-8 inflammatory and IGF-1 secretory profile of myeloma cells, an observation that raises important questions for therapeutic approaches incorporating the agent. More... »

PAGES

1801-1806

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2013.186

DOI

http://dx.doi.org/10.1038/bjc.2013.186

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000616297

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23632478


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunologic Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin-Like Growth Factor I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-8", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lenalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "CNRS, UMR 6299, 44000, Nantes, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "D\u00e9partement de Recherche en Canc\u00e9rologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France", 
            "Universit\u00e9 de Nantes, 44000, Nantes, France", 
            "CNRS, UMR 6299, 44000, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ma\u00efga", 
        "givenName": "S", 
        "id": "sg:person.01252207601.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252207601.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019h\u00e9matologie clinique CHU de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "D\u00e9partement de Recherche en Canc\u00e9rologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France", 
            "Universit\u00e9 de Nantes, 44000, Nantes, France", 
            "CNRS, UMR 6299, 44000, Nantes, France", 
            "Service d\u2019h\u00e9matologie clinique CHU de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gomez-Bougie", 
        "givenName": "P", 
        "id": "sg:person.01210057627.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210057627.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CNRS, UMR 6299, 44000, Nantes, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "D\u00e9partement de Recherche en Canc\u00e9rologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France", 
            "Universit\u00e9 de Nantes, 44000, Nantes, France", 
            "CNRS, UMR 6299, 44000, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bonnaud", 
        "givenName": "S", 
        "id": "sg:person.01111567152.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111567152.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CNRS, UMR 6299, 44000, Nantes, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "D\u00e9partement de Recherche en Canc\u00e9rologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France", 
            "Universit\u00e9 de Nantes, 44000, Nantes, France", 
            "CNRS, UMR 6299, 44000, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gratas", 
        "givenName": "C", 
        "id": "sg:person.0647042022.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647042022.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019h\u00e9matologie clinique CHU de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Service d\u2019h\u00e9matologie clinique CHU de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moreau", 
        "givenName": "P", 
        "id": "sg:person.0732370777.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732370777.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019h\u00e9matologie clinique CHU de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "D\u00e9partement de Recherche en Canc\u00e9rologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France", 
            "Universit\u00e9 de Nantes, 44000, Nantes, France", 
            "CNRS, UMR 6299, 44000, Nantes, France", 
            "Service d\u2019h\u00e9matologie clinique CHU de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Gouill", 
        "givenName": "S", 
        "id": "sg:person.015715754073.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015715754073.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CNRS, UMR 6299, 44000, Nantes, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "D\u00e9partement de Recherche en Canc\u00e9rologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France", 
            "Universit\u00e9 de Nantes, 44000, Nantes, France", 
            "CNRS, UMR 6299, 44000, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pellat-Deceunynck", 
        "givenName": "C", 
        "id": "sg:person.0576210230.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576210230.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CNRS, UMR 6299, 44000, Nantes, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "D\u00e9partement de Recherche en Canc\u00e9rologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France", 
            "Universit\u00e9 de Nantes, 44000, Nantes, France", 
            "CNRS, UMR 6299, 44000, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amiot", 
        "givenName": "M", 
        "id": "sg:person.0711145301.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711145301.41"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrc2536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050986935", 
          "https://doi.org/10.1038/nrc2536"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-04-30", 
    "datePublishedReg": "2013-04-30", 
    "description": "Background:Lenalidomide is an active immunomodulatory and antiproliferative agent in multiple myeloma. However, the molecular mechanisms driving these activities are not yet fully elucidated. Therefore, we investigated the modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment.Methods:Lenalidomide effect on myeloma cell proliferation was investigated in a myeloma cell line collection (n=23) by 3H-thymidine incorporation. Modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment was analysed by real-time quantitative PCR.Results:Lenalidomide inhibits the proliferation of two-thirds of myeloma cell lines independently of their genetic background. We demonstrated that LEN increased TNF-\u03b1 and IL-8 inflammatory cytokines and insulin-like growth factor-1 (IGF-1) growth factor in both sensitive and resistant myeloma cells to LEN.Conclusion:Lenalidomide favours a uniform TNF-\u03b1 and IL-8 inflammatory and IGF-1 secretory profile of myeloma cells, an observation that raises important questions for therapeutic approaches incorporating the agent.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.2013.186", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "108"
      }
    ], 
    "keywords": [
      "myeloma cells", 
      "lens treatment", 
      "multiple myeloma", 
      "IL-8 inflammatory cytokines", 
      "myeloma cell proliferation", 
      "growth factor profile", 
      "growth factor patterns", 
      "resistant myeloma cells", 
      "myeloma cell lines", 
      "lenalidomide effects", 
      "real-time quantitative PCR", 
      "inflammatory cytokines", 
      "IL-8", 
      "therapeutic approaches", 
      "secretory profile", 
      "lenalidomide", 
      "factor profile", 
      "factor patterns", 
      "growth factor", 
      "cell proliferation", 
      "myeloma", 
      "cell lines", 
      "TNF", 
      "antiproliferative agents", 
      "paradoxical effect", 
      "two-thirds", 
      "quantitative PCR", 
      "molecular mechanisms", 
      "cell line collection", 
      "treatment", 
      "cells", 
      "genetic background", 
      "proliferation", 
      "cytokines", 
      "agents", 
      "immunomodulatory", 
      "modulation", 
      "PCR", 
      "effect", 
      "profile", 
      "patterns", 
      "factors", 
      "activity", 
      "important questions", 
      "background", 
      "lens", 
      "mechanism", 
      "lines", 
      "line collection", 
      "collection", 
      "incorporation", 
      "observations", 
      "questions", 
      "approach"
    ], 
    "name": "Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma", 
    "pagination": "1801-1806", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000616297"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2013.186"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23632478"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2013.186", 
      "https://app.dimensions.ai/details/publication/pub.1000616297"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_598.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.2013.186"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.186'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.186'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.186'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.186'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      94 URIs      85 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2013.186 schema:about N3e75cb5d20cf4947bfde540890ed7981
2 N418d897169a640599e407791c3bb0640
3 N5c24ce27743a47a8854b517513979b25
4 N6d18d3bf93644dce904b02389a16eed3
5 N6f89eaafa3e4457da582175e26a7c129
6 N845450f45a114ab2aabddfb29dc110de
7 N890f3c73b99042a982e085c0a3c2f8c8
8 N993e461720e8419cb07641cb8a3bc78d
9 Na33ab0caf9b142b6922aa0f9a1c07f83
10 Nac1cc893b17e4842bcd90ca6d74c353c
11 Ncd667e9dcc3b479da07485655d833cee
12 Nebba519c6f74453aa5254a0ca176d4ed
13 Nf18076449f5d43b79ca5a3c88448f678
14 Nf7f3aec1ddae4e4aa213b3c863452077
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nae44d58fb98e4a489fac52191ea6f3e6
18 schema:citation sg:pub.10.1038/nrc2536
19 schema:datePublished 2013-04-30
20 schema:datePublishedReg 2013-04-30
21 schema:description Background:Lenalidomide is an active immunomodulatory and antiproliferative agent in multiple myeloma. However, the molecular mechanisms driving these activities are not yet fully elucidated. Therefore, we investigated the modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment.Methods:Lenalidomide effect on myeloma cell proliferation was investigated in a myeloma cell line collection (n=23) by 3H-thymidine incorporation. Modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment was analysed by real-time quantitative PCR.Results:Lenalidomide inhibits the proliferation of two-thirds of myeloma cell lines independently of their genetic background. We demonstrated that LEN increased TNF-α and IL-8 inflammatory cytokines and insulin-like growth factor-1 (IGF-1) growth factor in both sensitive and resistant myeloma cells to LEN.Conclusion:Lenalidomide favours a uniform TNF-α and IL-8 inflammatory and IGF-1 secretory profile of myeloma cells, an observation that raises important questions for therapeutic approaches incorporating the agent.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N246f256d3b5647dd9201ba48371593a1
25 N8235d5ef9324464d8535b770543f9e97
26 sg:journal.1017082
27 schema:keywords IL-8
28 IL-8 inflammatory cytokines
29 PCR
30 TNF
31 activity
32 agents
33 antiproliferative agents
34 approach
35 background
36 cell line collection
37 cell lines
38 cell proliferation
39 cells
40 collection
41 cytokines
42 effect
43 factor patterns
44 factor profile
45 factors
46 genetic background
47 growth factor
48 growth factor patterns
49 growth factor profile
50 immunomodulatory
51 important questions
52 incorporation
53 inflammatory cytokines
54 lenalidomide
55 lenalidomide effects
56 lens
57 lens treatment
58 line collection
59 lines
60 mechanism
61 modulation
62 molecular mechanisms
63 multiple myeloma
64 myeloma
65 myeloma cell lines
66 myeloma cell proliferation
67 myeloma cells
68 observations
69 paradoxical effect
70 patterns
71 profile
72 proliferation
73 quantitative PCR
74 questions
75 real-time quantitative PCR
76 resistant myeloma cells
77 secretory profile
78 therapeutic approaches
79 treatment
80 two-thirds
81 schema:name Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
82 schema:pagination 1801-1806
83 schema:productId N5ceb6c75540a464a969bb2015d80834c
84 N8a2129635c794b40a6edb1b81c35e49f
85 Ncb41cbacc4534c878ddd905c318b7305
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000616297
87 https://doi.org/10.1038/bjc.2013.186
88 schema:sdDatePublished 2022-10-01T06:38
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher Nbdf52557943243e48d39fb61af0da901
91 schema:url https://doi.org/10.1038/bjc.2013.186
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N039cb30b9bbd490cbcae4acd2acf2008 rdf:first sg:person.015715754073.62
96 rdf:rest Nee2484c808d74ee392156d8544da1db8
97 N1c6523a4d34a43df87ce2926d910bb84 rdf:first sg:person.01210057627.49
98 rdf:rest Nf70db31bf9d74a40ab1d7c628dc35fa3
99 N246f256d3b5647dd9201ba48371593a1 schema:issueNumber 9
100 rdf:type schema:PublicationIssue
101 N35051de1366e462aabc753a9474cefa4 rdf:first sg:person.0711145301.41
102 rdf:rest rdf:nil
103 N3e75cb5d20cf4947bfde540890ed7981 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Immunologic Factors
105 rdf:type schema:DefinedTerm
106 N418d897169a640599e407791c3bb0640 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Cell Line, Tumor
108 rdf:type schema:DefinedTerm
109 N5b78001101f9418fa049d15af3b05ed7 rdf:first sg:person.0647042022.28
110 rdf:rest N65c909c629f64c569fdaccfeca6ff7be
111 N5c24ce27743a47a8854b517513979b25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Insulin-Like Growth Factor I
113 rdf:type schema:DefinedTerm
114 N5ceb6c75540a464a969bb2015d80834c schema:name dimensions_id
115 schema:value pub.1000616297
116 rdf:type schema:PropertyValue
117 N65c909c629f64c569fdaccfeca6ff7be rdf:first sg:person.0732370777.35
118 rdf:rest N039cb30b9bbd490cbcae4acd2acf2008
119 N6d18d3bf93644dce904b02389a16eed3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Antineoplastic Agents
121 rdf:type schema:DefinedTerm
122 N6f89eaafa3e4457da582175e26a7c129 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Bone Marrow Cells
124 rdf:type schema:DefinedTerm
125 N8235d5ef9324464d8535b770543f9e97 schema:volumeNumber 108
126 rdf:type schema:PublicationVolume
127 N845450f45a114ab2aabddfb29dc110de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Interleukin-8
129 rdf:type schema:DefinedTerm
130 N890f3c73b99042a982e085c0a3c2f8c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 N8a2129635c794b40a6edb1b81c35e49f schema:name doi
134 schema:value 10.1038/bjc.2013.186
135 rdf:type schema:PropertyValue
136 N993e461720e8419cb07641cb8a3bc78d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Thalidomide
138 rdf:type schema:DefinedTerm
139 Na33ab0caf9b142b6922aa0f9a1c07f83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Cell Proliferation
141 rdf:type schema:DefinedTerm
142 Nac1cc893b17e4842bcd90ca6d74c353c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Tumor Necrosis Factor-alpha
144 rdf:type schema:DefinedTerm
145 Nae44d58fb98e4a489fac52191ea6f3e6 rdf:first sg:person.01252207601.19
146 rdf:rest N1c6523a4d34a43df87ce2926d910bb84
147 Nbdf52557943243e48d39fb61af0da901 schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 Ncb41cbacc4534c878ddd905c318b7305 schema:name pubmed_id
150 schema:value 23632478
151 rdf:type schema:PropertyValue
152 Ncd667e9dcc3b479da07485655d833cee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Angiogenesis Inhibitors
154 rdf:type schema:DefinedTerm
155 Nebba519c6f74453aa5254a0ca176d4ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Drug Resistance, Neoplasm
157 rdf:type schema:DefinedTerm
158 Nee2484c808d74ee392156d8544da1db8 rdf:first sg:person.0576210230.40
159 rdf:rest N35051de1366e462aabc753a9474cefa4
160 Nf18076449f5d43b79ca5a3c88448f678 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Multiple Myeloma
162 rdf:type schema:DefinedTerm
163 Nf70db31bf9d74a40ab1d7c628dc35fa3 rdf:first sg:person.01111567152.06
164 rdf:rest N5b78001101f9418fa049d15af3b05ed7
165 Nf7f3aec1ddae4e4aa213b3c863452077 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Lenalidomide
167 rdf:type schema:DefinedTerm
168 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
169 schema:name Medical and Health Sciences
170 rdf:type schema:DefinedTerm
171 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
172 schema:name Clinical Sciences
173 rdf:type schema:DefinedTerm
174 sg:journal.1017082 schema:issn 0007-0920
175 1532-1827
176 schema:name British Journal of Cancer
177 schema:publisher Springer Nature
178 rdf:type schema:Periodical
179 sg:person.01111567152.06 schema:affiliation grid-institutes:None
180 schema:familyName Bonnaud
181 schema:givenName S
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111567152.06
183 rdf:type schema:Person
184 sg:person.01210057627.49 schema:affiliation grid-institutes:grid.277151.7
185 schema:familyName Gomez-Bougie
186 schema:givenName P
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210057627.49
188 rdf:type schema:Person
189 sg:person.01252207601.19 schema:affiliation grid-institutes:None
190 schema:familyName Maïga
191 schema:givenName S
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252207601.19
193 rdf:type schema:Person
194 sg:person.015715754073.62 schema:affiliation grid-institutes:grid.277151.7
195 schema:familyName Le Gouill
196 schema:givenName S
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015715754073.62
198 rdf:type schema:Person
199 sg:person.0576210230.40 schema:affiliation grid-institutes:None
200 schema:familyName Pellat-Deceunynck
201 schema:givenName C
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576210230.40
203 rdf:type schema:Person
204 sg:person.0647042022.28 schema:affiliation grid-institutes:None
205 schema:familyName Gratas
206 schema:givenName C
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647042022.28
208 rdf:type schema:Person
209 sg:person.0711145301.41 schema:affiliation grid-institutes:None
210 schema:familyName Amiot
211 schema:givenName M
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711145301.41
213 rdf:type schema:Person
214 sg:person.0732370777.35 schema:affiliation grid-institutes:grid.277151.7
215 schema:familyName Moreau
216 schema:givenName P
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732370777.35
218 rdf:type schema:Person
219 sg:pub.10.1038/nrc2536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050986935
220 https://doi.org/10.1038/nrc2536
221 rdf:type schema:CreativeWork
222 grid-institutes:None schema:alternateName CNRS, UMR 6299, 44000, Nantes, France
223 schema:name CNRS, UMR 6299, 44000, Nantes, France
224 Département de Recherche en Cancérologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France
225 Université de Nantes, 44000, Nantes, France
226 rdf:type schema:Organization
227 grid-institutes:grid.277151.7 schema:alternateName Service d’hématologie clinique CHU de Nantes, Nantes, France
228 schema:name CNRS, UMR 6299, 44000, Nantes, France
229 Département de Recherche en Cancérologie Nantes/Angers, Inserm, UMR892, 8, quai Moncousu, Nantes 44007, France
230 Service d’hématologie clinique CHU de Nantes, Nantes, France
231 Université de Nantes, 44000, Nantes, France
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...